Clinical trials: Advanced Esophageal Cancer
Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
- Conditions
- Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer
- Trial name
- NCT03538028
- Testing
- INCAGN02385
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Incyte Biosciences International Sàrl
Advanced Upper Gastrointestinal Tract Adenocarcinoma
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
This randomized Phase 3 open-label study will compare the efficacy of the T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT) monoclonal antibody domvanalimab, the anti programmed cell…
- Trial name
- STAR-221 (NCT05568095)
- Testing
- Domvanalimab, Zimberelimab, Capecitabine
- Where
- 168 sites in United States, Argentina and 27 more
- Volunteers
- 1,040 people
- Sponsor
- Arcus Biosciences, Inc.
Advanced Esophageal Squamous Cell Cancer
Neoadjuvant Chemoradiotherapy Combined With Perioperative Toripalimab in Locally Advanced Esophageal Cancer
Neoadjuvant chemoradiotherapy (CRT) followed by surgery has become the standard treatment option for locally advanced esophageal squamous cell cancer (ESCC).
- Trial name
- NCT04437212
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- RenJi Hospital
Resectable Esophageal Squamous Cell Carcinoma
Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
This trial is conducted in patients with resectable locally advanced esophageal squamous cell carcinoma. The investigators plan to enroll 46 patients with resectable locally advanced esophageal cancer in Tianjin cancer hospital.
- Trial name
- NCT07457528
- Testing
- HLX10, Chemotherapy, Nimotuzumab
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms
A Study of SGN-STNV in Advanced Solid Tumors
This trial will look at a drug called SGN-STNV to find out whether it is safe for patients with solid tumors. It will study SGN-STNV to find out what its side effects are.
- Conditions
- Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms
- Trial name
- NCT04665921
- Testing
- SGN-STNV
- Where
- 18 sites in United States, Canada and 4 more
- Volunteers
- 111 people
- Sponsor
- Seagen Inc.
Esophageal Squamous Cell Carcinoma
Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC
Tislelizumab combined with chemotherapy sequential neoadjuvant therapy for non-cCR patients after neoadjuvant chemoradiotherapy in locally advanced ESCC.
- Trial name
- ETNT (NCT05189730)
- Testing
- Tirelizumab, Paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Esophageal Squamous Cell Carcinoma
A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma
This study is a multicentre, randomised, parallel-controlled, open-label, 3 phase clinical trial. The subjects were untreated, unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma with low…
- Trial name
- NCT05919030
- Testing
- Intensity-modulated radiotherapy (IMRT), Tislelizumab, Cisplatin
- Where
- China
- Volunteers
- 155 people
- Sponsor
- Renmin Hospital of Wuhan University
Esophageal Squamous Cell Carcinoma, Chemoradiation
Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCC
This clinical trial has two stages: phase II and phase III. Eligible patients will be randomized 1:1 to the two arms: paclitaxel plus cisplatin and cisplatin plus 5-fluorouracil.
- Trial name
- NCT03623737
- Testing
- neoadjuvant chemoradiation
- Where
- Taiwan
- Volunteers
- 248 people
- Sponsor
- National Taiwan University Hospital
Solid Tumors, Metastatic Melanoma
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
This is a first-in-human, open-label, multicenter, Phase I multiple-ascending dose (MAD) study of RO7247669, an anti PD-1 (programmed death-1) and LAG-3 (Lymphocyte-activation gene 3) bispecific antibody, for participants with…
- Conditions
- Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04140500
- Testing
- RO7247669
- Where
- 25 sites in Denmark, Georgia and 7 more
- Volunteers
- 170 people
- Sponsor
- Hoffmann-La Roche
Advanced Esophageal Carcinoma
mFOLFIRI Combine With Nimotuzumab Second Line Chemotherapy for Squamous-cell Carcinoma of the Esophagus
There are few studies about 2nd line treatment in advanced esophageal carcinoma (AEC), some showed that irinotecan may be effective.
- Trial name
- NCT01486992
- Testing
- mFOLFIRI+Nimotuzumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University
HER-2 Positive Gastric Cancer, Gastrooesophageal Cancer
Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment
The investigators are doing this research program to find out if the investigational drug, afatinib which is a medication known to block the function of the ErbB2 protein might help standard chemotherapy, in particular…
- Conditions
- HER-2 Positive Gastric Cancer, Gastrooesophageal Cancer, Esophageal Cancer
- Trial name
- NCT02274012
- Testing
- Afatinib, Paclitaxel
- Sponsor
- Columbia University
Metastatic Esophageal Cancer
Combination of Cryosurgery and NK Immunotherapy for Advanced Esophageal Cancer
The aim of this study is the safety and efficacy of cryosurgery plus NK immunotherapy to advanced esophageal cancer.
- Trial name
- NCT02843581
- Testing
- Cryosurgery, NK immunotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC)
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer
- Trial name
- NCT06943521
- Testing
- MT-4561
- Where
- 6 sites in United States, Japan
- Volunteers
- 27 people
- Sponsor
- Tanabe Pharma America, Inc.
Neoplasm
A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma
The primary purpose of this study is to evaluate objective response rate (ORR) as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of erdafitinib in a molecularly-defined subset of Asian participants with…
- Trial name
- NCT02699606
- Testing
- Erdafitinib
- Where
- 6 sites in China, South Korea and 1 more
- Volunteers
- 35 people
- Sponsor
- Janssen Research & Development, LLC
Solid Tumor
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of RMC-4630 and cobimetinib in adult participants with relapsed/refractory solid tumors with specific…
- Trial name
- NCT03989115
- Testing
- RMC-4630, Cobimetinib, Drug: Osimertinib
- Where
- 24 sites in United States, South Korea
- Volunteers
- 113 people
- Sponsor
- Revolution Medicines, Inc.
Adenocarcinoma of the Gastroesophageal Junction, Stage IIB Esophageal Adenocarcinoma
Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery
This randomized phase II trial studies how well regorafenib works in treating patients with cancer of the esophagus or gastroesophageal junction that has spread from where it started to nearby tissue or lymph nodes and have…
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Stage IIB Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma
- Trial name
- NCT02234180
- Testing
- Regorafenib
- Where
- 10 sites in United States
- Volunteers
- 3 people
- Sponsor
- Academic and Community Cancer Research United
Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
This is a nonrandomized, uncontrolled, open-label, multicenter Phase 2 study to evaluate the efficacy, safety, and tolerability of futibatinib in combination with PD-1 antibody-based SoC therapy in adult patients with solid…
- Conditions
- Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Siewert Type 1 GEJ Cancer
- Trial name
- NCT05945823
- Testing
- Futibatinib, Pembrolizumab, Cisplatin
- Where
- 22 sites in United States, France and 2 more
- Volunteers
- 53 people
- Sponsor
- Taiho Oncology, Inc.
Esophageal Cancer
Trilaciclib Combined With Concurrent Chemoradiotherapy and Immunotherapy in the Treatment of Esophageal Cancer
This study is a double-arm, randomized, controlled, single-center, phase II clinical trial aimed at evaluating the efficacy and safety of chemoradiotherapy plus immunotherapy with or without Trilaciclib in the treatment of…
- Trial name
- NCT06569459
- Testing
- Trilaciclib Injection [Cosela]
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Esophageal Carcinoma
Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer
In this study, participants with advanced or metastatic squamous cell carcinoma of the esophagus that has progressed after first-line standard therapy will be randomized to receive either single agent SHR-1210 or the…
- Trial name
- NCT03099382
- Testing
- camrelizumab, Docetaxel, Irinotecan
- Where
- 2 sites in China
- Volunteers
- 457 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Esophageal Cancer
Trial of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Cancer
This trial is going to evaluate the efficacy and safety of IMRT / nab-TP chemotherapy for unresectable esophageal cancer, and to investigate the optimal concurrent chemotherapy regimen for local advanced and unresectable…
- Trial name
- NCT02762474
- Testing
- nab-paclitaxel group
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital